Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:35:57.691Z.
Calculation as of: 2026-10-06T13:35:57.691Z.
Quote observation: 2026-10-06T13:35:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf0630fc9642b75147419b140bafddb7ccff0a2362c2d95f2dd7172ee2000ae5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$892.87M
Price/OCF Ratio
N/A
TTM Avg
1973.56
3Y Avg
1192.17
5Y Avg
1192.17
Market Cap
$917.68M
Price/OCF Ratio
12.78
TTM Avg
11.45
3Y Avg
13.28
5Y Avg
14.23
Market Cap
$892.20M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$851.97M
Price/OCF Ratio
N/A
TTM Avg
10.75
3Y Avg
10.75
5Y Avg
10.75
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $949.71M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $940.12M | N/A | 6.63 | 6.62 | 6.62 |
| Arbutus Biopharma Corp (ABUS)vs › | $892.87M | N/A | 1973.56 | 1192.17 | 1192.17 |
| HealthStream, Inc. (HSTM)vs › | $917.68M | 12.78 | 11.45 | 13.28 | 14.23 |
| Bioventus Inc. (BVS)vs › | $916.63M | 9.46 | 9.21 | 23.47 | 25.52 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $892.20M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $988.93M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $851.97M | N/A | 10.75 | 10.75 | 10.75 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | N/A | 517.11 | 517.11 | 517.11 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
